Prognostic factors in potentially resectable stage III non-small cell lung cancer receiving neoadjuvant treatment—a narrative review

• Published in: Translational lung cancer research 2021-01, Vol.10 (1), p.581-589
• Main Authors: Calvo, Virginia, Aliaga, Carlos, Carracedo, Carlos, Provencio, Mariano
• Format: Article
• Language: English
• ISSN: 2218-6751; 2226-4477
• DOI: 10.21037/tlcr-20-515

Lung cancer is the leading cause of cancer-related death in worldwide. The most important treatment for patients with stage I and II non-small cell lung cancer (NSCLC) is surgery. Resected stage II and III NSCLC patients should be offered adjuvant chemotherapy and in patients with resected stage IB disease and with a primary tumor >4 cm this treatment could be considered. The treatment of resectable locally advanced NSCLC should be evaluated within an experienced multidisciplinary team. Neoadjuvant chemotherapy can be considered in patients with resectable disease and clear candidates for complementary chemotherapy. Neoadjuvant chemotherapy has similar impact on overall survival (OS) than adjuvant chemotherapy, however postoperative chemotherapy has more evidence-based support. Immunotherapy is being studied in early and locally advanced NSCLC as a neoadjuvant or adjuvant treatment. Different prognostic factors have been described in patients with stage III who have received neoadjuvant treatment, which we intend to review in this article.